{
    "ticker": "VSTE",
    "name": "VistaGen Therapeutics, Inc.",
    "description": "VistaGen Therapeutics, Inc. is a clinical-stage biopharmaceutical company focused on developing innovative therapies for patients with central nervous system (CNS) diseases and disorders. Founded in 2008, VistaGen aims to transform the treatment landscape for mental health conditions by utilizing its proprietary drug development platform, which integrates advanced stem cell technology and predictive medicine. The company's lead product candidate, AV-101, is being developed for the treatment of major depressive disorder (MDD) and is designed to provide a novel approach to depression treatment without the side effects commonly associated with existing therapies. VistaGen\u2019s pipeline also includes AV-101 for the treatment of neuropathic pain and social anxiety disorder, among other indications. With a commitment to addressing the unmet needs in mental health, VistaGen is dedicated to advancing its clinical programs through rigorous research and patient engagement. The company collaborates with leading academic institutions and research organizations to enhance its drug development efforts, striving to bring meaningful improvements to the lives of patients suffering from debilitating CNS conditions.",
    "industry": [
        "Biotechnology",
        "Pharmaceuticals"
    ],
    "headquarters": "South San Francisco, California, USA",
    "founded": "2008",
    "website": "https://www.vistagen.com",
    "ceo": "Sharon Mates",
    "social_media": {
        "twitter": "https://twitter.com/VistaGen",
        "linkedin": "https://www.linkedin.com/company/vistagen-therapeutics/"
    },
    "investor_relations": "https://ir.vistagen.com",
    "key_executives": [
        {
            "name": "Sharon Mates",
            "position": "CEO"
        },
        {
            "name": "Ernest Mario",
            "position": "Chairman"
        },
        {
            "name": "Gary R. Carlsen",
            "position": "CFO"
        }
    ],
    "product_categories": [
        {
            "category": "Therapeutic Candidates",
            "products": [
                "AV-101"
            ]
        }
    ],
    "seo": {
        "meta_title": "VistaGen Therapeutics, Inc. | Innovative CNS Therapies",
        "meta_description": "Explore VistaGen Therapeutics, Inc., a leader in developing innovative therapies for CNS disorders. Learn about their clinical-stage programs and commitment to mental health.",
        "keywords": [
            "VistaGen",
            "Biotechnology",
            "CNS Disorders",
            "Mental Health",
            "AV-101",
            "Pharmaceuticals"
        ]
    },
    "faq": [
        {
            "question": "What is VistaGen known for?",
            "answer": "VistaGen is known for developing innovative therapies for central nervous system disorders, particularly major depressive disorder."
        },
        {
            "question": "Who is the CEO of VistaGen?",
            "answer": "Sharon Mates is the CEO of VistaGen Therapeutics, Inc."
        },
        {
            "question": "Where is VistaGen headquartered?",
            "answer": "VistaGen is headquartered in South San Francisco, California, USA."
        },
        {
            "question": "What is VistaGen's lead product candidate?",
            "answer": "VistaGen's lead product candidate is AV-101, aimed at treating major depressive disorder."
        },
        {
            "question": "When was VistaGen founded?",
            "answer": "VistaGen was founded in 2008."
        }
    ],
    "competitors": [
        "PTON",
        "SAGE",
        "AXSM",
        "VRNA"
    ],
    "related_stocks": [
        "AMGN",
        "GILD",
        "REGN",
        "BIIB"
    ]
}